Nonetheless, in contrast to Ad-CMV-Tom-treated tumours, Ad-Smad6-treated tumours presented less variable CD31+ expression intensity across blood vessels and showed fewer (smaller) CD31 marker gaps (Fig. 5G). This evidence concerns the gene PECAM1 and neoplasm.